What the Research Actually Says About Why Is My A1C Still High?

What the Research Actually Says About Why Is My A1C Still High?

You followed the plan. You swapped refined carbs for vegetables, reduced portion sizes, and started moving more. Yet at your next lab appointment, your A1C was still high — maybe even higher than before. This is one of the most demoralizing experiences in preventive health, and it's far more common than most clinicians acknowledge.

A1C measures your average blood glucose over roughly 90 days, reflecting what's attached to hemoglobin in your red blood cells. But the reasons it stays elevated are rarely just "eating too much sugar." The actual drivers are layered: fasting hyperglycemia that persists overnight, postprandial glucose spikes that average out poorly, insulin resistance at the cellular level, inflammation, and in many cases, intertwined lipid abnormalities that compound glycemic risk. This article unpacks each of those mechanisms with the clinical evidence behind them.

---

Why Is My Fasting Glucose Still High?

For many people working to lower their A1C, fasting glucose is the sticking point. Even after dinner is cleaned up and evening snacking is eliminated, morning readings stay stubbornly in the 110–130 mg/dL range. This is often the dawn phenomenon — a normal physiological cortisol and growth hormone surge in the early morning hours that signals the liver to release glucose into the bloodstream. In people with insulin resistance, the insulin response to that release is blunted, so glucose climbs rather than stays flat.

Research confirms that fasting hyperglycemia contributes disproportionately to A1C in people whose overall glucose is in the moderately elevated range. A study published in Diabetes Care found that in individuals with A1C between 7.3% and 9.2%, fasting plasma glucose accounted for the majority of A1C elevation compared to postprandial contributions — meaning targeting fasting glucose specifically is critical for this cohort (Monnier et al., Diabetes Care 2003; PMID: 12663580).

The liver's overnight glucose output is heavily regulated by insulin sensitivity in hepatic tissue. Strategies that improve hepatic insulin sensitivity — including reduced visceral adiposity, improved sleep architecture, time-restricted eating windows, and specific micronutrients — have meaningful impact on fasting glucose independent of what you eat for dinner.

Berberine, a plant alkaloid, has received significant clinical attention for its ability to inhibit hepatic glucose production via AMPK activation. A meta-analysis of 27 randomized controlled trials (2,569 participants) found berberine reduced fasting blood glucose by an average of 19.83 mg/dL compared to placebo, with effects comparable in magnitude to metformin in some subgroups (Dong et al., Evidence-Based Complementary and Alternative Medicine 2012; PMID: 23118793). While berberine is not a replacement for medication, this mechanism is clinically relevant to the fasting glucose problem.

Chromium picolinate is another well-studied micronutrient in this context. Chromium potentiates insulin receptor signaling, and multiple trials show it can reduce fasting glucose in insulin-resistant individuals. A systematic review and meta-analysis of 15 RCTs found chromium supplementation significantly reduced fasting blood glucose in people with type 2 diabetes, with a pooled reduction of approximately 16.3 mg/dL (Abdollahi et al., Journal of Pharmacy and Pharmaceutical Sciences 2013; PMID: 24393558).

For people asking "why is my fasting glucose still high even on a good diet," the answer is often hepatic insulin resistance and the dawn phenomenon — two targets that require more than dietary carbohydrate restriction alone.

---

Why Is My Triglycerides Still High?

High triglycerides and high A1C frequently travel together — and for good reason. They share a root cause: excess carbohydrate and calorie intake relative to metabolic capacity, combined with insulin resistance. When insulin can't efficiently move glucose into cells, the liver packages the overflow as very-low-density lipoprotein (VLDL) particles loaded with triglycerides. The result is elevated triglycerides and elevated blood glucose at the same time.

High triglycerides matter beyond the lipid panel. Elevated triglycerides are associated with smaller, denser LDL particles — the phenotype most strongly linked to cardiovascular risk in metabolic syndrome — and they impair the function of HDL, reducing its cardioprotective capacity. For someone trying to understand persistent A1C elevation, high triglycerides are a red flag that insulin resistance is driving the picture more than dietary sugar alone.

Omega-3 fatty acids (EPA and DHA) are among the most robustly studied interventions for triglyceride reduction. A meta-analysis of 21 RCTs found that omega-3 supplementation reduced triglycerides by a mean of 34 mg/dL in people with elevated baseline levels, with higher-dose regimens producing larger reductions (Balk et al., Journal of Nutrition 2006; PMID: 16365086). The mechanism involves reduced hepatic VLDL synthesis and enhanced triglyceride clearance from circulation.

Importantly, addressing triglycerides is not just about cardiovascular risk — it's about glycemic health. Triglyceride-rich lipoprotein excess worsens the inflammatory environment that further impairs insulin signaling. Lowering triglycerides is, in part, an insulin-sensitizing strategy.

For people whose triglycerides remain elevated despite cutting refined carbohydrates, the residual contributors often include alcohol intake, inadequate omega-3 status, and disrupted sleep (cortisol-driven hepatic fat output). Learning about omega-3 dosing for metabolic health can help contextualize how much EPA/DHA actually moves the needle.

---

Why Is My ApoB Still High?

Apolipoprotein B (ApoB) is the protein that coats every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Measuring ApoB gives you the total count of artery-wall-penetrating particles, which is increasingly recognized as superior to LDL-C alone for cardiovascular risk stratification. If your ApoB is elevated alongside a high A1C, you are dealing with compounding cardiovascular risk that goes beyond what either marker captures alone.

Insulin resistance directly elevates ApoB by driving hepatic overproduction of VLDL-ApoB particles. This is why metabolic syndrome — characterized by central adiposity, high triglycerides, low HDL, elevated blood pressure, and high fasting glucose — is fundamentally an ApoB-elevation disorder as much as a glucose disorder. The American Heart Association has noted that non-HDL cholesterol and ApoB are superior predictors of atherosclerotic cardiovascular disease compared to LDL-C, particularly in people with metabolic syndrome or diabetes (AHA Scientific Statement on Lipid Management, 2018).

Reducing ApoB in the context of insulin resistance requires both targeting hepatic VLDL output and improving LDL receptor clearance. The former is addressed partly through insulin sensitization strategies and omega-3 supplementation; the latter is heavily influenced by diet (reducing saturated fat intake) and, in clinical settings, statin or PCSK9 inhibitor therapy.

For people asking "why is my ApoB still high" while managing blood sugar, the honest answer is that the same insulin resistance driving your A1C is also driving your liver to overproduce atherogenic particles. They are the same disease, expressed through different biomarkers. Addressing blood sugar and cardiovascular risk together is more effective than treating them sequentially.

---

Why Is My Lp(a) Still High?

Lp(a) — lipoprotein(a) — is a genetically determined lipoprotein that is largely unresponsive to diet and exercise. If your Lp(a) is above 50 mg/dL (or 125 nmol/L in molar units), it represents a fixed, inherited cardiovascular risk factor. Unlike triglycerides and ApoB, Lp(a) elevation is not a consequence of insulin resistance or poor metabolic health — it is mostly determined by the LPA gene locus and does not meaningfully change with lifestyle modification.

This is a critical distinction for someone trying to understand a comprehensive metabolic lab panel. High A1C reflects glycemic dysregulation that is usually modifiable. High Lp(a) reflects a genetic risk that is largely not modifiable with current available interventions (though RNA-targeting therapies are in late-stage trials as of 2024). Conflating the two — or expecting that the same interventions will fix both — leads to frustration and inappropriate expectations.

What Lp(a) elevation does do, clinically, is amplify the cardiovascular damage that high A1C and insulin resistance cause. In the presence of vascular inflammation, elevated oxidized LDL, and endothelial dysfunction — all of which high A1C worsens — Lp(a) particles are more likely to deposit in arterial walls. This is why people with both high A1C and high Lp(a) need aggressive glycemic management even if the Lp(a) itself cannot be lowered through lifestyle.

Niacin was historically studied as an Lp(a)-lowering agent and does reduce Lp(a) by roughly 20–30% in clinical trials, though its clinical utility was questioned after the AIM-HIGH and HPS2-THRIVE trials failed to show cardiovascular outcome benefit on top of statin therapy. Consulting a cardiologist or lipidologist is essential when Lp(a) is significantly elevated.

---

What This Means for Your Formula

If your A1C is persistently high, the relevant question isn't just "what supplement lowers blood sugar?" — it's "what are the specific mechanisms driving my glucose dysregulation, and what does the evidence say addresses each one?"

Ones builds personalized formulas precisely for this kind of multi-variable picture. After analyzing your blood work — including A1C, fasting glucose, triglycerides, ApoB, and other metabolic markers — the Ones AI identifies which mechanisms are most active for you and selects ingredients from its clinically validated catalog accordingly.

For the fasting glucose and insulin sensitivity pathway, Ones incorporates Berberine at evidence-supported doses aligned with the RCT literature showing AMPK activation and hepatic glucose output reduction. For the triglyceride and lipid dysregulation pathway, Omega-3 (EPA/DHA) is included at clinical doses — the same EPA/DHA range studied in trials showing 30+ mg/dL triglyceride reductions. And for the broader inflammatory and endocrine environment that compounds insulin resistance, Ones offers its Endocrine Support system blend, which targets the hormonal signaling pathways that directly affect glucose metabolism and cortisol-driven fasting hyperglycemia.

None of these are one-size-fits-all recommendations. A formula for someone with high fasting glucose, elevated triglycerides, and poor sleep looks different from one for someone with postprandial spikes and normal lipids. That individual calibration — based on your actual lab data — is the core of what Ones is built to do.

If you're navigating a complex metabolic picture, understanding how personalized supplement formulas are built from lab results can help clarify what to expect from a data-driven approach.

---

Key Takeaways

• A1C persistence is rarely one problem. Fasting hyperglycemia, postprandial spikes, hepatic insulin resistance, sleep disruption, and lipid dysregulation all contribute independently and simultaneously.
• Fasting glucose and the dawn phenomenon are major A1C drivers in the moderately elevated range; chromium and berberine have clinical evidence for hepatic insulin sensitization.
• High triglycerides are a glycemic signal, not just a lipid one — they reflect the same VLDL overproduction that insulin resistance drives, and omega-3s at clinical doses are the best-studied intervention.
• ApoB elevation and high A1C are expressions of the same root pathology — insulin resistance driving hepatic lipoprotein overproduction — and need to be addressed together, not sequentially.
• Lp(a) is genetically determined and largely unresponsive to lifestyle or supplements; its presence amplifies cardiovascular risk from A1C elevation but requires different clinical management.
• Personalized supplementation based on your specific lab findings — not generic blood sugar support blends — is what the evidence supports for addressing multi-marker metabolic dysfunction.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your supplement regimen or diabetes management plan.